中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (12): 1092-1096.doi: 10.35541/cjd.20210473

• 研究报道 • 上一篇    下一篇

奥马珠单抗治疗27例人工荨麻疹回顾分析

宋晓婷1    刘擘1    陈玉迪2    于淼1，3    廖双璐1    栾婷婷1，3    赵作涛1   

  1. 1北京大学第一医院皮肤性病科  国家皮肤与免疫疾病临床医学研究中心  北京市皮肤病分子诊断重点实验室  100034；2北京医院皮肤科  国家老年医学中心  中国医学科学院老年医学研究院  100730；3北京大学护理学院  100191
  • 收稿日期:2021-06-25 修回日期:2021-09-21 发布日期:2021-12-01
  • 通讯作者: 赵作涛 E-mail:zhaozuotaotao@163.com
  • 基金资助:
    国家自然科学基金中德合作项目（GZ901）

Retrospective analysis of omalizumab in the treatment of 27 cases of symptomatic dermographism

Song Xiaoting1, Liu Bo1, Chen Yudi2, Yu Miao1,3, Liao Shuanglu1, Luan Tingting1,3, Zhao Zuotao1   

  1. 1Department of Dermatology and Venereology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China; 2Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China; 3Peking University School of Nursing, Beijing 100191, China
  • Received:2021-06-25 Revised:2021-09-21 Published:2021-12-01
  • Contact: Zhao Zuotao E-mail:zhaozuotaotao@163.com
  • Supported by:
    Joint Sino-German Research Project of National Natural Science Foundation of China and DFG（GZ901）

PDF

5

摘要： 【摘要】 目的 通过分析真实世界奥马珠单抗治疗人工荨麻疹的数据，评估奥马珠单抗治疗人工荨麻疹的临床疗效和安全性。方法 回顾分析北京大学第一医院皮肤科门诊2018年2月到2021年5月完成16周奥马珠单抗治疗的人工荨麻疹病例资料，比较治疗前后关键摩擦阈值（CFT）和激发试验瘙痒评分、荨麻疹控制评分（UCT）、皮肤病生活质量指数（DLQI）、慢性荨麻疹生活质量问卷（CU-Q2oL），记录治疗期间患者报告的不良事件。治疗前后组内数据比较采用Wilcoxon符号秩和检验。结果 纳入27例完成16周奥马珠单抗治疗的人工荨麻疹患者。27例患者基线期CFT均为4，UCT为7.0（5.0，8.0）分，DLQI为9.0（6.0，10.0）分，CU-Q2oL为63.0（50.0，72.0）分。在治疗第4周，9例（33.3%）患者CFT由4降为0，27例患者UCT评分上升至14.0（12.0，16.0）分（Z = 4.548，P＜0.05），DLQI下降至2.0（0.0，2.0）分（Z = 4.513，P＜0.05），CU-Q2oL下降至32.0（25.0，41.0）分（Z = 4.433，P＜0.05）。治疗第16周，UCT升至15.0（14.0，16.0）分，DLQI降至0.0（0.0，1.0）分，CU-Q2oL降至25.0（23.0，30.0）分。治疗期间无药物相关严重不良事件报告。结论 奥马珠单抗可有效改善人工荨麻疹的症状，提高患者生活质量，且具有良好的安全性。

关键词: 荨麻疹, 治疗结果, 人工荨麻疹, 奥马珠单抗

Abstract: 【Abstract】 Objective To evaluate clinical efficacy and safety of omalizumab in the treatment of symptomatic dermographism by analyzing real-world data. Methods Clinical data were collected from patients with symptomatic dermographism who completed 16-week treatment with omalizumab in Department of Dermatology, Peking University First Hospital from February 2018 to May 2021, and retrospectively analyzed. The analysis was done by comparing data obtained before and after the treatment, including critical friction thresholds（CFTs）, pruritus scores in a provocation test, as well as urticaria control test （UCT）, dermatology life quality index （DLQI） and chronic urticaria quality of life questionnaire（CU-Q2oL）scores. Adverse events reported by patients during the treatment were recorded. Wilcoxon signed-rank test was applied for the analysis of clinical data before and after the treatment. Results A total of 27 patients with symptomatic dermographism who completed 16 weeks of omalizumab treatment were included. At baseline, the CFTs of all the 27 patients were 4, and their UCT, DLQI and CU-Q2oL scores were 7.0 （5.0, 8.0）, 9.0 （6.0, 10.0）, 63.0 （50.0, 72.0） points respectively. At week 4, the CFTs decreased from 4 to 0 in 9 patients （33.3%）, the UCT scores increased to 14.0 （12.0, 16.0） points （Z = 4.548, P＜0.05）, and the DLQI and CU-Q2oL scores decreased to 2.0 （0.0, 2.0） and 32.0 （25.0, 41.0） points respectively in the 27 patients （Z = 4.513, 4.433, respectively, both P＜0.05）. At week 6, the UCT scores increased to 15.0 （14.0, 16.0） points, and the DLQI and CU-Q2oL scores decreased to 0.0 （0.0, 1.0） and 25.0 （23.0, 30.0） points respectively in the 27 patients. No drug-related serious adverse events were reported during the treatment. Conclusion Omalizumab can effectively improve the symptoms of symptomatic dermographism and patients′ quality of life with a good safety profile.

Key words: Urticiaria, Treatment outcome, Dermographism, Omalizumab